The Measurable Residual Disease (MRD) Testing Implementation Roadmap is an innovative learning tool that can help multidisciplinary cancer care teams obtain the knowledge they need to implement, expand, and sustain MRD testing for patients with B-cell acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM). This Roadmap provides healthcare professionals with key information on how to lay the groundwork for MRD testing, train and prepare care teams to offer testing, implement the program, and evaluate ongoing progress. "Expert Insights" from the Advisory Committee that informed the Roadmap give teams a deeper understanding of how MRD testing fits into their cancer program. Online pre- and post-assessments in the Roadmap enable teams to gauge their progress throughout the process of implementing MRD testing for their patients.
Resources from the four components of the Implementation Roadmap provide additional information and are available in the Resource Library. The color-coded boxes in the Resource Library match the Roadmap journey, making it easy to find relevant resources quickly.
Program resources for Adult B-Cell ALL are sponsored by:
Program resources for CLL and Multiple Myeloma are sponsored by: